The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $324,836 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Flowpoint Medical Inc. in Overland Park, KS. The funding will be used to refine the manufacturability and operational parameters of an implantable device that aims to improve vascular access and safety for hemodialysis patients. Key product development activities include using state-of-the-art materials and engineering techniques, as well as conducting a large animal preclinical study to evaluate the device's functionality, tissue integration, inflammatory profile, and infection/bleeding risks. This novel device has the potential to make hemodialysis treatments safer, more efficient, and easier to administer, ultimately improving quality of life for dialysis patients and enabling wider adoption of home-based hemodialysis.
Generated 3/4/25, 2:19 AM